Aroa Biosurgery Gains Further Validation for Endoform® According to a Published Study

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Aroa Biosurgery Limited has gained further validation for Endoform®, its flagship extracellular matrix (ECM), with a new study published in the respected international peer-reviewed journal PLOS ONE.

The paper, titled ‘A novel chemotactic factor derived from the extracellular matrix protein decorin recruits mesenchymal stromal cells in vitro and in vivo’, stems from a collaborative study between the Aroa scientific team and scientists from Victoria University in Wellington, New Zealand and Charles River Laboratories in Germany.

Aroa BioSurgery lead scientist for the study, Dr. Sandi Dempsey, said the paper describes the ability of components found within the Endoform® ECM platform technology to signal stem cells in laboratory models.

“Endoform® contains a vast number of proteins that interact with a patient’s own cells to support the repair of damaged tissue in different ways. This data suggests that one such mechanism occurs by recruiting stem cells from the surrounding healthy tissue to support soft tissue repair,” Dr. Dempsey says.

Dr. Barnaby May, co-author of the study and Aroa’s Vice President of Research and Clinical Development said, “These recent findings provide further peer-reviewed validation of how the Endoform® ECM technology performs a critical role in soft tissue repair. Endoform® is an advanced bioscaffold with a rich composition of proteins that naturally occur in humans and help the body to regenerate. That we have shown Endoform® attracts stem cells to the site of tissue damage goes one step further towards unlocking the full regenerative capacity of Endoform®.”

Aroa’s CEO Brian Ward said the findings build on extensive pre-clinical and clinical research on Endoform® over the past 10 years as the company continues to focus on improving the rate and quality of healing in complex wounds and soft tissue reconstruction.

The published study also identified a novel protein component found in all tissue, dubbed ‘MayDay’ after the lead authors Dr. Barnaby May (Aroa) and Dr. Darren Day (Victoria University of Wellington).

‘MayDay’ was shown to communicate with stem cells and could play an important role during normal soft tissue repair such as wound healing, and further studies will be ongoing to understand the role that ‘MayDay’ plays in soft tissue repair.

Endoform® is derived from ovine (sheep) forestomach and includes a basement membrane layer and propria-submucosa (supportive connective tissue). It acts as a scaffold to grow new tissue lost or damaged through disease or injury, allowing the patient’s own cells to grow into the matrix to build new tissue and re-establish blood supply. As the patient continues to heal, this is replaced by their own tissue.

Aroa has five commercial products approved for sale in the US-based on the Endoform® technology, which have been used in more than four million procedures targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Aroa has regulatory clearance in more than 37 countries and a deep patent portfolio.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles